uBriGene Biosciences

Shanghai, CN · Boston, MA
Find alternatives to uBriGene Biosciences for AAV →
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
56.5
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (20) ○ EMA GMP ○ MHRA GMP

Quick Facts: uBriGene Biosciences

Signal Score
56.5/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
Shanghai, CN · Boston, MA
Modalities
AAV, Lentiviral, Plasmid
Active Programs
No ClinicalTrials.gov matches confirmed — 11 partnership signals in press (announcements, not verified)
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About uBriGene Biosciences

Chinese CGT CDMO with US presence. BIOSECURE Act exposure.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 11 partnership announcements found in press monitoring.
Programs — no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Plasmid
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 50.0
BIOSECURE Act exposure risk
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
BIOSECURE Act exposure risk
Capacity 63.0
2 manufacturing sites
Sites: Shanghai, China, Boston, MA
Source: company profiles (manufacturing sites, modality breadth)
2 manufacturing sites
Press Signals20 articles (not scored)
2 manufacturing sites

Hiring Activity 1 open role Beta

From public job postings on uBriGene Biosciences' careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
1
open role
0
in manufacturing, quality, PD/MSAT, engineering or regulatory (0%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 0 new postings, 0 taken down.
By function
Commercial, BD & client projects 1
By site
Germantown, MD
· 1 other
1
Latest postings
Associated Director of Marketing Commercial, BD & client projects · Germantown, MD
Coverage: counted from uBriGene Biosciences' own careers board. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: ubrigenebiosciences.applytojob.com · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Company Signals 20 articles

Company announcements, not verified evidence. They do not change any score.
partnership 2026-03-30
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Digital Journal
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies  Digital Journal
partnership 2026-03-30
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Corsicana Daily Sun
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies  corsicanadailysun.com
partnership 2026-03-30
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - The Facts
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies  The Facts
partnership 2026-03-30
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Weatherford Democrat
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies  Weatherford Democrat
general 2026-03-30
uBriGene and Cellinfinity BIO Partner to Advance In Vivo CAR-T Therapies - National Today
uBriGene and Cellinfinity BIO Partner to Advance In Vivo CAR-T Therapies  National Today
partnership 2026-03-30
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - PharmiWeb.com
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies  PharmiWeb.com
partnership 2026-03-30
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Yahoo Finance
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies  Yahoo Finance
partnership 2026-03-30
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - News-Press NOW
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies  News-Press NOW
partnership 2026-03-30
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - The Batesville Daily Guard
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies  The Batesville Daily Guard
partnership 2026-03-30
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Carroll County Mirror-Democrat
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies  Carroll County Mirror-Democrat
partnership 2026-03-30
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Scott Coop
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies  Scott Coop
partnership 2026-03-30
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Newswire.com
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies  newswire.com
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Gene - pharmiweb.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Gene  PharmiWeb.com
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - Rutland Herald
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy  Rutland Herald
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - BioSpace
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy  BioSpace
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - Weatherford Democrat
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy  weatherforddemocrat.com
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - ACCESS Newswire
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy  ACCESS Newswire
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - guardonline.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy  The Batesville Daily Guard
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - newswire.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy  newswire.com
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - theglobeandmail.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy  The Globe and Mail

Frequently Asked Questions About uBriGene Biosciences

What is uBriGene Biosciences's CDMO Signal Score?
uBriGene Biosciences has a Signal Score of 56/100, based on quality, operations, financial stability, and capacity data.
Evaluating uBriGene Biosciences for a manufacturing program?
Use the free AI matchmaker to compare uBriGene Biosciences against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs → Plasmid CDMOs →

Similar CDMOs

Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 82.9
AAV, Lentiviral, Plasmid, mRNA
Ascend Advanced Therapies
Rockville, MD · Alachua, FL · Munich, DE
Signal Score: 78.1
AAV, Lentiviral, Plasmid
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 77.6
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid, Small Molecule API, Oral Solid Dose, Sterile Fill-Finish

Compare uBriGene Biosciences with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on uBriGene Biosciences
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.